Recombinant DNA Advisory Committee- 9/12-13/94 
XIII. Continuation of the Discussion Regarding Proposed Amendments 
to Sections I, III, IV, V, and Appendix M of the NIH Guidelines 
Regarding NIH and FDA Consolidated Review of Human Gene Transfer 
Protocols/Drs. Wivel and Noguchi 43 
XIV. Addition to Appendix D of the NIH Guidelines Regarding a Human 
Gene Transfer Protocol Entitled: Retroviral-Mediated Transfer 
of the Iduronate-2-Sulfatase Gene into Lymphocytes for 
Treatment of Mild Hunter Syndrome (Mucopolysaccharidosis 
Type II) /Dr. Whitley 48 
XV. Clarification on NIH/FDA Consolidated Review/Dr. Walters 55 
XVI. Report from the Working Group on Retrovirus Vectors/Dr. Wivel 55 
XVn. Addition to Appendix D of the NIH Guidelines Regarding a Human 
Gene Transfer Protocol Entitled: Arterial Gene Transfer for 
Therapeutic Angiogenesis in Patients with Peripheral Artery 
Disease/ Drs. Isner and Walsh 56 
XVm. Addition to Appendix D of the NIH Guidelines Regarding a Human 
Gene Transfer Protocol Entitled: Treatment of Advanced CNS 
Malignancy with the Recombinant Adenovirus H5.020RSVTK : A 
Phase I Trial /Drs. Eck and Alavi 62 
XIX. Addition to Appendix D of the NIH Guidelines Regarding a Human 
Gene Transfer Protocol Entitled: Treatment of Advanced 
Mesothelioma with the Recombinant Adenovirus H5.020RSVTK 
A Phase I Trial /Dr. Albelda 69 
XX. Closing Remarks and Future Meeting Dates of the RAC 73 
XX3. Adjournment 74 
Attachment I - Roster 
II - Protocol List 
III - Minor Modifications 
IV - Acronyms 
[ 10 ] 
Recombinant DNA Research, Volume 20 
